The Nova Scotia Department of Health and CancerCare Nova Scotia has formally reviewed Afinitor and has officially made the decision to DECLINE funding.
We had had great hope that Nova Scotia would show leadership in covering this therapy as it did for Torisel in the first-line setting. Unfortunately those hopes have not been realized for second-line treatment. Nova Scotia’s denial is the first in the country and comes before the official Joint Oncology Drug Review recommendation.
Please see their statement here.
“The predicted budget impact in 2010/11 is $162,225 (6 patients), in Year 2 is $189,263 (7 patients) and
in Year 3 is $216, 300 (8 patients).”
So for those 6 patients this year, and 7 or 8 patients in the next years, you will not have funding for Afinitor,
even though there is no question of benefit: “Everolimus [Afinitor] was associated with a decrease in risk of progression and increase in stability rate.”
The Progression Free survival time –on average — of 4.9 months is not enough? Some patients, as we know, have done very, very well on Afinitor. We are not averages or statistics, but individuals facing a life-threatening disease.
Kidney Cancer Canada will be requesting a meeting with the key reimbursement managers in Nova Scotia to discuss this very unfortunate decision.
Please note: We would very much like to hear from patients in Nova Scotia — whether you have received Afinitor or not — to help us build our case to help other patients.
We cannot let kidney cancer patients in Nova Scotia go without second-line treatment for their disease. In January 2010, patients will face drug costs of $6,000 per month.
Please get in touch with us and help us fight this decision. Email to email@example.com